PE20091344A1 - Arilindenopirimidinas como antagonistas del receptor a2a de adenosina - Google Patents

Arilindenopirimidinas como antagonistas del receptor a2a de adenosina

Info

Publication number
PE20091344A1
PE20091344A1 PE2008001819A PE2008001819A PE20091344A1 PE 20091344 A1 PE20091344 A1 PE 20091344A1 PE 2008001819 A PE2008001819 A PE 2008001819A PE 2008001819 A PE2008001819 A PE 2008001819A PE 20091344 A1 PE20091344 A1 PE 20091344A1
Authority
PE
Peru
Prior art keywords
disease
adenosine
receptor
arylindenopyrimidines
antagonists
Prior art date
Application number
PE2008001819A
Other languages
English (en)
Inventor
Brian C Shook
Paul F Jackson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20091344A1 publication Critical patent/PE20091344A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

REFERIDO A UN COMPUESTO DE FORMULA A, SOLVATOS, HIDRATOS, TAUTOMEROS Y SUS SALES. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES ANTAGONISTA DEL RECEPTOR A2A DE ADENOSINA. SIENDO UTIL PARA EL TRATAMIENTO DE ENFERMEDAD DE PARKINSON, MAL DE HUNTINGTON, ATROFIAS DE SISTEMAS MULTIPLES, DEGENERACION CORTICOBASAL, ENFERMEDAD DE ALZHEIMER, DEMENCIA SENIL, ENTRE OTROS
PE2008001819A 2007-10-24 2008-10-23 Arilindenopirimidinas como antagonistas del receptor a2a de adenosina PE20091344A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98224707P 2007-10-24 2007-10-24

Publications (1)

Publication Number Publication Date
PE20091344A1 true PE20091344A1 (es) 2009-09-24

Family

ID=40091927

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001819A PE20091344A1 (es) 2007-10-24 2008-10-23 Arilindenopirimidinas como antagonistas del receptor a2a de adenosina

Country Status (12)

Country Link
US (1) US8017614B2 (es)
EP (1) EP2217575A1 (es)
JP (1) JP2011500819A (es)
CN (1) CN101835759A (es)
AR (1) AR069009A1 (es)
AU (1) AU2008317034A1 (es)
CL (1) CL2008003131A1 (es)
PA (1) PA8801501A1 (es)
PE (1) PE20091344A1 (es)
TW (1) TW200934493A (es)
UY (1) UY31420A1 (es)
WO (1) WO2009055308A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105540A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
DE112010005848B4 (de) * 2010-09-06 2016-03-10 Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences Amidverbindungen
WO2013156614A1 (en) 2012-04-20 2013-10-24 Ucb Pharma S.A. Methods for treating parkinson's disease
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127510A1 (en) 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
BR0318521A (pt) 2003-10-03 2006-09-12 Ortho Mcneil Pharm Inc arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados

Also Published As

Publication number Publication date
CN101835759A (zh) 2010-09-15
UY31420A1 (es) 2009-04-30
CL2008003131A1 (es) 2010-02-19
JP2011500819A (ja) 2011-01-06
EP2217575A1 (en) 2010-08-18
TW200934493A (en) 2009-08-16
US8017614B2 (en) 2011-09-13
WO2009055308A1 (en) 2009-04-30
US20090111827A1 (en) 2009-04-30
AR069009A1 (es) 2009-12-23
AU2008317034A1 (en) 2009-04-30
PA8801501A1 (es) 2009-05-15

Similar Documents

Publication Publication Date Title
CO6331340A2 (es) Pirrolo-pirimidinas y pirrolo piridinas
DOP2013000181A (es) Moduladores del receptor de glucagon
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
CO2018002829A2 (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm)
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
CU20120013A7 (es) Derivados de oxacina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
CL2012001348A1 (es) Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry.
CU20090133A7 (es) Compuestos tricíclicos y sus composiciones
AR057222A1 (es) Agonistas del receptor del neuropeprtido -2
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
UY30835A1 (es) 8-alquinilxantinas y derivados
CR8270A (es) Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PE20151001A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
CR10963A (es) Compuestos de 2-amino pirimidina
AR078434A1 (es) Sales de tetrazol-1-il- fenoximetil-tiazol-2-il- piperinidil- pirimidina sustituida
AR067328A1 (es) Formas amorfas estabilizadas de mesilato de imatinib
UY30558A1 (es) Derivados de pirazol como agentes antiagregantes plaquetarios y antitromboticos
NO20090779L (no) 5,6-bisaryl-2-pyridin-karboksamidderivater, fremstilling og anvendelse derav i terapeutika som uretosin II receptorantagonister
UY30916A1 (es) Derivados del 1-[sustituido]--3-[sustituido]-1-azona-biciclo[2,2,2]octano y sus enantiomeros
CL2016001348A1 (es) Forma cristalina de clorhidrato de (s)-(2-(6-cloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona; composición farmacéutica que la comprende; y su uso para el tratamiento o prevención de trastornos del sueño, tales como disomnias, parasomnias, entre otras.
ECSP10010597A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas

Legal Events

Date Code Title Description
FC Refusal